Want to see EVAX full AI Analyst Report?
Top Page
Evaxion Biotech
(NASDAQ:EVAX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$3.00
▲(1.35% Upside)
Action:Reiterated
Date:07/14/26
The score is held down primarily by weak financial performance (ongoing losses and negative cash flow with continued funding dependence) and bearish technicals (price below major moving averages with negative MACD). These are partially offset by a constructive earnings call focused on encouraging EVX-01/platform updates and a stated cash runway into H2 2027, while valuation inputs are limited due to negative earnings and no dividend yield provided.
Positive Factors
Clinically validated AI‑Immunology platform
Clinical validation across three oncology trials materially reduces platform technical risk and supports durable differentiation. That evidence strengthens licensing and partnership prospects, increases the likelihood of technology transfer across indications, and underpins a platform-led business model over the next 2–6 months and beyond.
Negative Factors
Finite cash runway into H2 2027
A runway that extends only into H2 2027 without assumed partnerships forces near‑term financing or dealmaking. This constraint can delay programs, compress negotiating leverage with potential partners, and raise the probability of dilution or program prioritization decisions that affect long‑term growth and execution continuity.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinically validated AI‑Immunology platform
Clinical validation across three oncology trials materially reduces platform technical risk and supports durable differentiation. That evidence strengthens licensing and partnership prospects, increases the likelihood of technology transfer across indications, and underpins a platform-led business model over the next 2–6 months and beyond.
Read all positive factors
Evaxion Biotech (EVAX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.60M
Dividend YieldN/A
Average Volume (3M)20.50K
Price to Earnings (P/E)―
Beta (1Y)1.90
Revenue Growth127.03%
EPS Growth87.33%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.53
Shares Outstanding8,340,215
10 Day Avg. Volume13,703
30 Day Avg. Volume20,495
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.79
Price to Sales (P/S)4.06
P/FCF Ratio-4.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.25Price Target Upside280.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$5.27M
Evaxion Biotech Business Overview & Revenue Model
Company Description
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio fe...
How the Company Makes Money
Evaxion is a clinical-stage biotech and, as such, its business model has historically been centered on funding research and development rather than generating recurring product sales. The company’s potential and existing sources of cash and revenu...
Evaxion Biotech Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 20, 2026
Earnings Call Sentiment Positive
The call conveyed strong R&D and platform momentum, highlighted by robust EVX-01 immunogenicity (86% immunogenicity and de novo response rates), supportive clinical signals (75% overall response rate previously reported), platform scalability into GBM (fully personalized designs for 24/24 cases, with 21/24 designs including both neoantigen and ERV components), and novel vaccine concepts (polio work with The Gates Foundation). The company also reinforced disciplined financial management and confirmed cash runway into H2 2027. Key risks discussed include a finite cash runway, a Q1 net loss of USD 3.6M and reduced equity, and the absence of finalized partnerships to extend funding or accelerate certain programs. On balance, the positive clinical and platform developments materially outweigh the financial and partnership uncertainties, though the latter remain important near-term considerations.Positive Updates
EVX-01 Strong Immunogenicity in Phase II
EVX-01 Phase II translational data showed an 86% immunogenicity conversion rate and 86% de novo T-cell response rate, demonstrating broad and novel T-cell activation. The call also reported a positive correlation between predicted vaccine-target quality and magnitude of T-cell response, supporting the predictive power of the AI-Immunology platform.
Negative Updates
Finite Cash Runway and Funding Risk
Cash and equivalents of USD 18.4 million and an expected 2026 burn of ~USD 14 million imply runway into H2 2027, leaving the company dependent on partnerships or financing to fund operations beyond that point. Management acknowledged the runway figure explicitly and noted projections are made without assumed partnerships.
Read all updates
Q1-2026 Updates
Positive
Negative
EVX-01 Strong Immunogenicity in Phase II
EVX-01 Phase II translational data showed an 86% immunogenicity conversion rate and 86% de novo T-cell response rate, demonstrating broad and novel T-cell activation. The call also reported a positive correlation between predicted vaccine-target quality and magnitude of T-cell response, supporting the predictive power of the AI-Immunology platform.
Read all positive updates
Company Guidance
Management's guidance reiterated disciplined financial and development plans: an expected operating cash burn of roughly USD 14.0M for 2026, cash and equivalents of $18.4M at quarter end supporting runway into H2 2027 (assuming no new deals), a Q1 net loss of $3.6M and total equity of $13.2M, with operating expenses broadly flat (R&D up slightly, G&A down modestly). On the program and milestone side, EVX‑01 delivered an 86% vaccine target immunogenicity rate and 86% de novo T‑cell responses (prior clinical readouts cited a 75% overall response rate, 25 complete responders and 92 sustained responses), the last patient/last visit in the Phase II extension is complete, and 3‑year clinical outcome data are expected in H2 2026; EVX‑04 is targeted for clinical readiness by year‑end 2026; the AI‑Immunology platform is described as clinically validated (3/3 oncology trials) and scalable (24 GBM patient designs feasible: 21/24 included both neoantigens and ER antigens, 2 neoantigen‑only, 1 ER‑only), and management emphasized continued partnership discussions across the platform and assets.Evaxion Biotech Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.53M | 7.53M | 3.34M | 73.00K | 0.00 | 0.00 |
| Gross Profit | 7.53M | 7.53M | 3.34M | 73.00K | 0.00 | 0.00 |
| EBITDA | -10.87M | -7.12M | -9.79M | -21.40M | -22.57M | -24.21M |
| Net Income | -9.76M | -7.71M | -10.57M | -22.13M | -23.17M | -24.53M |
Balance Sheet | ||||||
| Total Assets | 23.64M | 28.41M | 12.48M | 12.89M | 22.02M | 40.16M |
| Cash, Cash Equivalents and Short-Term Investments | 18.44M | 23.23M | 5.05M | 4.18M | 13.18M | 32.17M |
| Total Debt | 0.00 | 7.50M | 10.10M | 10.87M | 10.26M | 3.69M |
| Total Liabilities | 10.44M | 11.37M | 14.14M | 17.62M | 13.72M | 7.73M |
| Stockholders Equity | 13.21M | 17.04M | -1.65M | -4.73M | 8.30M | 32.44M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -6.66M | -12.94M | -17.78M | -26.07M | -23.29M |
| Operating Cash Flow | 0.00 | -6.65M | -12.94M | -17.69M | -25.77M | -21.93M |
| Investing Cash Flow | 0.00 | -14.04K | -3.00K | -93.00K | -268.00K | -1.33M |
| Financing Cash Flow | 0.00 | 22.48M | 13.13M | 10.69M | 7.85M | 49.80M |
Evaxion Biotech Technical Analysis
Negative
2.96
Price Trends
3.38
Negative
3.72
Negative
4.34
Negative
Market Momentum
-0.14
Negative
38.16
Neutral
25.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVAX, the sentiment is Negative. The current price of 2.96 is below the 20-day moving average (MA) of 3.04, below the 50-day MA of 3.38, and below the 200-day MA of 4.34, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 38.16 is Neutral, neither overbought nor oversold. The STOCH value of 25.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVAX.
Evaxion Biotech Risk Analysis
Evaxion Biotech disclosed 117 risk factors in its most recent earnings report. Evaxion Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Evaxion Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $463.13M | 5.85 | 230.68% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $90.36M | -3.35 | -1136.50% | ― | 417.63% | 91.39% | |
49 Neutral | $40.01M | 0.68 | -560.64% | ― | -32.64% | 56.66% | |
48 Neutral | $23.60M | -1.84 | -73.56% | ― | 127.03% | 87.33% | |
46 Neutral | $78.36M | -7.81 | -185.74% | ― | 45.88% | 34.17% | |
44 Neutral | $24.97M | -3.44 | -94.51% | ― | ― | ― |
* Healthcare Sector Average
EVAX
Evaxion Biotech
2.82
0.10
3.68%
IGC
IGC Pharma
0.25
-0.10
-28.24%
QTTB
Q32 Bio
15.68
13.75
712.44%
VRCA
Verrica Pharmaceuticals
5.22
-0.35
-6.28%
ELUT
Elutia
0.86
-1.13
-56.98%
NRXS
NeurAxis, Inc.
6.25
3.73
148.02%
Evaxion Biotech Corporate Events
Evaxion to Unveil Three-Year EVX-01 Melanoma Data at ESMO 2026
Jul 17, 2026
On July 17, 2026, Evaxion announced plans to present three-year clinical efficacy data from its phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma at the ESMO Congress 2026 in Madrid in October. The new dataset, generated fro...
Evaxion Unveils Promising Preclinical Data for AI-Designed CMV Vaccine EVX-V1
Jul 13, 2026
On July 12, 2026, Evaxion presented new preclinical data for its cytomegalovirus vaccine program EVX-V1 at the International Herpesvirus Workshop in Montreal, underscoring the promise of its AI-driven, multi-component design. The data in CMV-infec...
Evaxion Showcases AI-Driven CMV Vaccine Data Ahead of International Herpesvirus Workshop
Jul 1, 2026
On July 1, 2026, Evaxion A/S announced it will present new preclinical data for its next-generation cytomegalovirus (CMV) vaccine candidate EVX-V1 at the International Herpesvirus Workshop in Montreal, with a poster session scheduled for July 12, ...
Evaxion Wins 2026 Prix Galien UK Award for AI-Immunology Digital Health Platform
Jun 12, 2026
On June 12, 2026, Evaxion announced that its AI-Immunology platform had received the 2026 Prix Galien UK Award for Best digital health solution, selected by a jury of leading scientific and healthcare experts from among 10 candidates. The accolade...
Evaxion Unveils Promising Preclinical Data for AI-Designed AML Vaccine EVX-04
Jun 11, 2026
On June 11, 2026, Evaxion A/S reported new preclinical data for EVX-04, its off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia, showing that the AI-designed construct is correctly expressed and secreted in human cells, enabling...
Evaxion to Showcase New EVX-04 AML Vaccine Data at EHA 2026
May 12, 2026
On May 12, 2026, Evaxion A/S reported that it will present new preclinical data on EVX-04, its AI-designed off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the European Hematology Association 2026 Congress in Stockholm. The poster,...
Evaxion Posts Q1 2026 Results as AI-Immunology Platform Hits Key Cancer Vaccine Milestone
May 7, 2026
On May 7, 2026, Evaxion reported a strong operational start to the year, highlighting new data showing its AI-Immunology platform correctly identified vaccine targets in 86% of cases for its EVX-01 personalized melanoma vaccine and confirming scal...
Evaxion Biotech Schedules Q1 2026 Results and Business Update for May 7
May 4, 2026
On May 4, 2026, Evaxion A/S, a Nasdaq-listed clinical-stage TechBio firm, filed a Form 6-K in the United States to incorporate a new press release into its existing shelf and registration statements. The filing underscores the company’s ongo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.